• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新药与新担忧:通过对慢性丙型肝炎患者直接抗病毒药物的药物警戒获取见解

New drugs and new concerns: Gaining insight through Pharmacovigilance of direct acting Anti-Viral's in chronic HCV patients.

作者信息

Hashmi Zahid Yasin, Zia Muhammad Qasim, Bajwa Akram, Ahmed Maqsood, Anwer Naveed, Raza Mahwish, Baqar Jaffer Bin

机构信息

Zahid Yasin Hashmi, FCPS Liver Center Faisalabad, Pakistan.

Muhammad Qasim Zia, FCPS Allama Iqbal Memorial Teaching Hospital, Sialkot, Pakistan.

出版信息

Pak J Med Sci. 2021 Mar-Apr;37(2):299-304. doi: 10.12669/pjms.37.2.3400.

DOI:10.12669/pjms.37.2.3400
PMID:33679903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7931287/
Abstract

OBJECTIVE

The study aimed to assess the safety profile of Direct Acting Anti-Viral's (DAAs) among patients with chronic Hepatitis C Virus (HCV).

METHODS

This multicenter, analytical cross-sectional study was conducted in six gastroenterology and Hepatology centers including Liver Center Faisalabad, Allama Iqbal Medical Institute and Liver Center DHQ Hospital Sialkot, Isra Hospital Hyderabad, Allied Hospital Faisalabad and Rehman Medical Institute Peshawar, between May 2018 and May 2019. The data regarding patient demographics, treatment plan and the frequency of Adverse Events (AEs), and their severity was collected using a pre-designed questionnaire and analyzed through SPSS version 20.0.

RESULTS

A total of 511 HCV patients were enrolled, with an overall male majority. Around 66.3% patients experienced a total of 419 AEs, out of which 61 events were suspected from DAAs while remaining 317 events were associated with Ribavirin. Pyrexia (24.6%) and fatigue (14.8%) were the most commonly reported AEs among patients receiving DAAs. Factors such as Ribavirin-based treatments and the presence of Cirrhosis were more likely to promote AEs occurrence OR [95%CI] i.e. 5.2(2.3-9.1) and 1.9(1.1-3.1) respectively (p < 0.05).

CONCLUSION

It is concluded from the study results that DAAs have displayed promising outcomes due to the minimal and minor AEs reported.

摘要

目的

本研究旨在评估直接作用抗病毒药物(DAAs)在慢性丙型肝炎病毒(HCV)患者中的安全性。

方法

本多中心分析性横断面研究于2018年5月至2019年5月在六个胃肠病学和肝病中心进行,包括费萨拉巴德肝脏中心、阿拉马·伊克巴勒医学院和锡亚尔科特DHQ医院肝脏中心、海得拉巴伊斯拉医院、费萨拉巴德联合医院和白沙瓦雷曼医学院。使用预先设计的问卷收集有关患者人口统计学、治疗方案、不良事件(AE)发生频率及其严重程度的数据,并通过SPSS 20.0版进行分析。

结果

共纳入511例HCV患者,男性总体占多数。约66.3%的患者共经历了419次AE,其中61次事件怀疑由DAAs引起,其余317次事件与利巴韦林有关。发热(24.6%)和疲劳(14.8%)是接受DAAs治疗患者中最常报告的AE。基于利巴韦林的治疗和肝硬化等因素更有可能促进AE的发生,比值比[95%置信区间]分别为5.2(2.3 - 9.1)和1.9(1.1 - 3.1)(p < 0.05)。

结论

从研究结果得出结论,由于报告的AE最少且轻微,DAAs显示出了有前景的结果。

相似文献

1
New drugs and new concerns: Gaining insight through Pharmacovigilance of direct acting Anti-Viral's in chronic HCV patients.新药与新担忧:通过对慢性丙型肝炎患者直接抗病毒药物的药物警戒获取见解
Pak J Med Sci. 2021 Mar-Apr;37(2):299-304. doi: 10.12669/pjms.37.2.3400.
2
Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis.索磷布韦与维帕他韦联合用药治疗伴或不伴肝硬化的慢性丙型肝炎患者的疗效与安全性
Cureus. 2021 Nov 20;13(11):e19768. doi: 10.7759/cureus.19768. eCollection 2021 Nov.
3
Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.埃及法尤姆省慢性丙型肝炎病毒感染直接作用抗病毒药物的药物不良反应研究——一项药物警戒研究
Curr Drug Saf. 2018;13(3):187-195. doi: 10.2174/1574886313666180716111529.
4
Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil.用于慢性丙型肝炎治疗的直接作用抗病毒药物:巴西两个高等院校中心的经验。
World J Hepatol. 2022 Jan 27;14(1):195-208. doi: 10.4254/wjh.v14.i1.195.
5
Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.丙型肝炎病毒(HCV)感染及HCV/人类免疫缺陷病毒(HIV)合并感染患者中直接抗病毒药物的真实安全性和疗效
HIV Med. 2017 Apr;18(4):284-291. doi: 10.1111/hiv.12429. Epub 2016 Aug 1.
6
Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.接受基于索磷布韦或不含索磷布韦的直接抗病毒药物治疗的慢性丙型肝炎患者估算肾小球滤过率的变化
J Hepatol. 2020 May;72(5):839-846. doi: 10.1016/j.jhep.2019.11.014. Epub 2019 Nov 29.
7
Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.与物质使用障碍和慢性丙型肝炎患者直接作用抗病毒药物相关的医疗保健利用和费用。
J Manag Care Spec Pharm. 2021 Oct;27(10):1388-1402. doi: 10.18553/jmcp.2021.27.10.1388.
8
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.直接作用抗病毒药物治疗丙型肝炎病毒感染血友病患者的持续病毒学应答率高:一项多中心研究
Liver Int. 2020 May;40(5):1062-1068. doi: 10.1111/liv.14337. Epub 2020 Jan 6.
9
Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis.接受新型直接抗病毒药物治疗的慢性丙型肝炎患者的皮肤不良事件:一项系统评价和荟萃分析。
J Cutan Med Surg. 2016 Jan;20(1):58-66. doi: 10.1177/1203475415595775. Epub 2015 Jul 10.
10
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.奥比他韦、帕利瑞韦、利托那韦和利巴韦林联合治疗埃及丙型肝炎病毒基因型 4 感染合并或不合并代偿性肝硬化患者(AGATE-II):一项多中心、3 期、部分随机、开放标签试验。
Lancet Gastroenterol Hepatol. 2016 Sep;1(1):36-44. doi: 10.1016/S2468-1253(16)30002-4. Epub 2016 Jun 16.

引用本文的文献

1
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.直接作用抗病毒药物治疗丙型肝炎病毒患者的安全性评价:一项药物警戒研究。
Ther Innov Regul Sci. 2023 Sep;57(5):997-1007. doi: 10.1007/s43441-023-00537-x. Epub 2023 May 25.

本文引用的文献

1
Adverse Drug Events in Older Adults: Review of Adjudication Methods in Deprescribing Studies.老年人药物不良反应:减药研究中裁定方法的综述。
J Am Geriatr Soc. 2020 Jul;68(7):1594-1602. doi: 10.1111/jgs.16382. Epub 2020 Mar 6.
2
Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China.中国单中心研究:直接作用抗病毒药物治疗 HCV 感染肾移植受者的长期随访结果。
BMC Infect Dis. 2019 Jul 19;19(1):645. doi: 10.1186/s12879-019-4217-7.
3
The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients.丙型肝炎病毒患者接受直接抗病毒治疗后肝细胞癌的发生率
Pak J Med Sci. 2019 Jan-Feb;35(1):101-105. doi: 10.12669/pjms.35.1.109.
4
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.基于索磷布韦的治疗方案在丙型肝炎病毒感染患者中的应用:中国的真实世界经验。
Can J Gastroenterol Hepatol. 2018 Nov 13;2018:3908767. doi: 10.1155/2018/3908767. eCollection 2018.
5
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.巴基斯坦抗丙型肝炎病毒感染直接抗病毒药物的现状
Medicina (Kaunas). 2018 Nov 5;54(5):80. doi: 10.3390/medicina54050080.
6
Genetic diversity of Hepatitis C Virus in Pakistan using Next Generation Sequencing.利用下一代测序技术研究巴基斯坦丙型肝炎病毒的遗传多样性。
J Clin Virol. 2018 Nov;108:26-31. doi: 10.1016/j.jcv.2018.09.001. Epub 2018 Sep 8.
7
Study of Adverse Drug Effects of Direct-Acting Antivirals for Chronic HCV Infection at Fayoum Governorate, Egypt - A Pharmacovigilance Study.埃及法尤姆省慢性丙型肝炎病毒感染直接作用抗病毒药物的药物不良反应研究——一项药物警戒研究
Curr Drug Saf. 2018;13(3):187-195. doi: 10.2174/1574886313666180716111529.
8
Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.遏制巴基斯坦丙型肝炎病毒流行:扩大治疗和预防以实现消除的影响。
Int J Epidemiol. 2018 Apr 1;47(2):550-560. doi: 10.1093/ije/dyx270.
9
Effectiveness and Safety of Sofosbuvir in Treatment-NäiveChildren with Hepatitis C Infection.索磷布韦在初治丙型肝炎感染儿童中的有效性和安全性。
J Coll Physicians Surg Pak. 2017 Jul;27(7):423-426.
10
Sofosbuvir For The Treatment Of Hepatitis C Genotype 3 Infected Patients In Pakistan.索磷布韦用于治疗巴基斯坦丙型肝炎3型感染患者。
J Ayub Med Coll Abbottabad. 2016 Oct-Dec;28(4 Suppl 1):S884-S889.